These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16962721)

  • 1. Estrogen or testosterone may be effective agents in the management of both multiple myeloma and Alzheimer's disease.
    Ozen M; Karaahmet F; Tezcan ME; Bulut N; Altundag K
    Med Hypotheses; 2007; 68(1):231-2. PubMed ID: 16962721
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.
    Khong T; Sharkey J; Spencer A
    Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of interleukin-6 in multiple myeloma.
    Bataille R; Klein B
    Ann Med Interne (Paris); 1992; 143 Suppl 1():77-9. PubMed ID: 1300892
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro.
    Morinaga A; Hirohata M; Ono K; Yamada M
    Biochem Biophys Res Commun; 2007 Aug; 359(3):697-702. PubMed ID: 17559807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between obesity and multiple myeloma in postmenopausal women may be attributed to increased aromatization of androgen in adipose tissue.
    Islam R; Altundag K; Kurt M; Altundag O; Turen S
    Med Hypotheses; 2005; 65(5):1001-2. PubMed ID: 16002233
    [No Abstract]   [Full Text] [Related]  

  • 8. More than a decade of estrogen neuroprotection.
    Simpkins JW; Singh M
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S131-6. PubMed ID: 18631989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
    Roher AE; Kokjohn TA
    Alzheimers Dement; 2009 Sep; 5(5):437-8. PubMed ID: 19751925
    [No Abstract]   [Full Text] [Related]  

  • 10. Effective pharmacologic management of Alzheimer's disease.
    Farlow MR; Cummings JL
    Am J Med; 2007 May; 120(5):388-97. PubMed ID: 17466645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
    Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
    Crouch PJ; Barnham KJ; Bush AI; White AR
    Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Terpos E
    Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
    Kreft AF; Martone R; Porte A
    J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
    [No Abstract]   [Full Text] [Related]  

  • 17. Alzheimer's disease as copper deficiency.
    Klevay LM
    Med Hypotheses; 2008; 70(4):802-7. PubMed ID: 17928161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen, beta-amyloid metabolism/trafficking, and Alzheimer's disease.
    Xu H; Wang R; Zhang YW; Zhang X
    Ann N Y Acad Sci; 2006 Nov; 1089():324-42. PubMed ID: 17261779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: the lipid connection.
    Hartmann T; Kuchenbecker J; Grimm MO
    J Neurochem; 2007 Nov; 103 Suppl 1():159-70. PubMed ID: 17986151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.